Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Equity Average for 14 consecutive years, with $1.2 billion as the latest value for Q1 2026.

  • For Q1 2026, Equity Average fell 23.45% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $1.2 billion, down 23.45%, while the annual FY2025 figure was $1.4 billion, 16.25% up from the prior year.
  • Equity Average hit $1.2 billion in Q1 2026 for Agios Pharmaceuticals, down from $1.2 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.6 billion in Q4 2024 and bottomed at $702.2 million in Q2 2024.
  • Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2024.
  • Year-over-year, Equity Average plummeted 41.98% in 2022 and then surged 101.94% in 2025.
  • Agios Pharmaceuticals' Equity Average stood at $1.1 billion in 2022, then fell by 21.07% to $848.9 million in 2023, then skyrocketed by 86.57% to $1.6 billion in 2024, then dropped by 21.79% to $1.2 billion in 2025, then decreased by 7.07% to $1.2 billion in 2026.
  • According to Business Quant data, Equity Average over the past three periods came in at $1.2 billion, $1.2 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.